BioTech firm ReViral, which is focused on discovering, developing, and commercialising novel antiviral therapeutics, has closed a £33m ($44m) funding round.
The Hertfordshire-based firm, which has an office in North Carolina, USA has focused its efforts on treatment of Respiratory Syncytial Virus (RSV) which affects 64 million people annually.
The Series C financing was led by CR-CP Life Science Fund, with additional investment from Andera Partners, Brace Pharma Capital, Green Sands Equity, New Leaf Venture Partners, Novo Holdings, OrbiMed Advisors, and Perceptive Advisors.
Jason Zhou M.D., CEO and Managing Director of CR-CP Life Science Fund, joins the ReViral Board of Directors.
“We are delighted by the strong financial support from this leading syndicate of healthcare investors, and we welcome Jason to our Board”, said Alex Sapir, CEO, ReViral.
“The proceeds from the financing will be used to support Phase 2 clinical development for sisunatovir, our wholly-owned fusion protein inhibitor, and to progress our N-protein replication inhibitor program into Phase 1.”
Dr. Zhou added: “We are pleased to invest in ReViral and support their work to develop and commercialize novel therapeutics to treat RSV, a major global health concern. We have confidence that ReViral’s world class management team, strong science, and deep clinical expertise will enable ReViral to become a leader in the RSV market.”